Elanco Animal Health (ELAN) Tops Q2 EPS by 6c, Beats on Revenue; Offers FY24 Guidance

Elanco Animal Health (NYSE: ELAN) reported Q2 EPS of $0.30, $0.06 better than the analyst estimate of $0.24. Revenue for the quarter came in at $1.18 billion versus the consensus estimate of $1.15 billion.

GUIDANCE:

Elanco Animal Health sees FY2024 EPS of $0.88-$0.96, versus the consensus of $0.94. Elanco Animal Health sees FY2024 revenue of $4.41-4.46 billion, versus the consensus of $4.47 billion.

For earnings history and earnings-related data on Elanco Animal Health (ELAN) click here.

You May Also Be Interested In

• Cerebras Systems (CBRS) Misses Q1 EPS, Revenues Beat
• Enanta Pharma loses appeal in Pfizer Paxlovid patent case
• Bernstein SocGen Group Reiterates Outperform Rating on Hermes International (RMS:FP) (HESAY) after cautious commentary